MESOBLAST FPO [MSB] (MSB.AX)
Develops cell-based medicines to treat inflammatory diseases, heart failure, and chronic pain.
2.04-0.01%Healthcare
StockGlow Score
Neutral
BearishBullish
1 year ago-13.2%
The outlook
Mesoblast is trading near its 52-week lows with analysts holding a strong buy consensus and an average price target about 89% above the current level. The stock sits below both its 50- and 200-day moving averages, suggesting a longer-term downtrend. Overall sentiment is neutral despite the bullish analyst view.
What’s behind the score
Analyst consensusStrong Buy — 1.2 avg of 4 analysts
Price trendBelow its 50- & 200-day averages
52-week range11% of the way from its 52-week low to high
Price targetAvg target +89% vs current price
Analyst price target
~12-month · 4 analysts3.85average target+88.6% vs now
Now 2.04
Low 3.00High 4.71
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$2.65B
52-wk high
3.31
52-wk low
1.88
50-day avg
2.13
200-day avg
2.34
Trailing P/E
—